Recombinant human C1 inhibitor (conestat alfa): In the treatment of angioedema attacks in hereditary angioedema

BioDrugs

Volumn 26, Issue 5, 2012, Pages 315-323

  Plosker, Greg L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Profiles; Hereditary angioedema

Indexed keywords

ANTIBODY; C REACTIVE PROTEIN; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C1S INHIBITOR ANTIBODY; COMPLEMENT COMPONENT C4; HEMOGLOBIN; IMMUNOGLOBULIN E ANTIBODY; PLACEBO; UNCLASSIFIED DRUG;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ARTICLE; BACKACHE; DIARRHEA; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DEGRADATION; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; ERYTHEMA; HEADACHE; HEMATOCRIT; HERPES SIMPLEX; HUMAN; KIDNEY FAILURE; MENSTRUATION DISORDER; NAUSEA; ORAL PARESTHESIA; PARESTHESIA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; SCROTAL SWELLING; SIDE EFFECT; SINGLE DRUG DOSE; SINUSITIS; SORE THROAT; SWELLING; TONSILLITIS; TOOTH ABSCESS; URINARY TRACT INFECTION; URTICARIA; VERTIGO;

ANGIOEDEMAS, HEREDITARY; ANIMALS; CLINICAL TRIALS AS TOPIC; COMPLEMENT C1 INHIBITOR PROTEIN; COMPLEMENT INACTIVATING AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 84866120236     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.2165/11206880-000000000-00000     Document Type: Article

References (36)

1. Longhurst H, Cicardi M. Hereditary angio-oedema. Lancet 2012 Feb 4; 379: 474-81
2. Bowen T, Cicardi M, Bork K, et al. Hereditary angioedema: A current stateof- the-art review, VII: Canadian Hungarian 2007 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema. Ann Allergy Asthma Immunol 2008 Jan; 100 (1 Suppl. 2): S30-40
3. Davis III AE, et al. New treatments addressing the pathophysiology of hereditary angioedema. Clin Mol Allergy 2008 Apr 18; 14 (6): 2
4. Zuraw BL. Hereditary angioedema.NEngl J Med 2008 Sep 4; 359 (10): 1027-36
5. Davis III AE. The pathophysiology of hereditary angioedema. Clin Immunol 2005 Jan; 114 (1): 3-9
6. Bork K, Meng G, Staubach P, et al.Hereditary angioedema: newfindings concerning symptoms, affected organs, and course. Am J Med 2006Mar; 119 (3): 267-74
7. Frazer-Abel A, Giclas PC. Update on laboratory tests for the diagnosis and differentiation of hereditary angioedema and acquired angioedema. Allergy Asthma Proc 2011 Sep-Oct; 32 Suppl. 1: S17-21
8. Pharming Group N.V. Ruconest- EU summary of product characteristics [online]. Available from URL: Http://www.ema.europa.eu/docs/en-GB/doc ument-library/EPAR-Product-Information/human/001223/WC500098542.pdf [Accessed 2012 Jan 26]
9. Zanichelli A, Vacchini R, Badini M, et al. Standard care impact on angioedema because of hereditaryC1 inhibitor deficiency: A 21-month prospective study in a cohort of 103 patients. Allergy 2011 Feb; 66 (2): 192-6
10. Prematta MJ, Kemp JG, Gibbs JG, et al. Frequency, timing, and type of prodromal symptoms associated with hereditary angioedema attacks. Allergy Asthma Proc 2009 Sep-Oct; 30 (5): 506-11
11. Cicardi M, Bork K, Caballero T, et al. Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: Consensus report of an International Working Group. Allergy 2012; 67: 147-57
12. Bowen T, Cicardi M, Farkas H, et al. 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol 2010; 6 (1): 24
13. Bork K, TriggianiM, Caballero T, et al. A review of hereditary angioedema and recombinant human C1 inhibitor treatment. Eur Respir Dis 2011; 7 (1): 32-5
14. Hack CE, Johansson S. C1-inhibitor therapy in hereditary angioedema: Mechanistic implications [abstract no. 34]. J Angioedema 2011; (Special Preview Edition printed for the 7th C1 Inhibitor Deficiency Workshop): 27
15. Choi G, Soeters MR, Farkas H, et al. Recombinant human C1-inhibitor in the treatment of acute angioedema attacks. Transfusion (Paris) 2007 Jun 1; 47 (6): 1028-32
16. van Doorn MB, Burggraaf J, van Dam T, et al. A phase I study of recombinant human C1 inhibitor in asymptomatic patients with hereditary angioedema. J Allergy Clin Immunol 2005 Oct; 116 (4): 876-83
17. Koles K, van Berkel PH, Mannesse ML, et al. Influence of lactation parameters on the N-glycosylation of recombinant human C1 inhibitor isolated from the milk of transgenic rabbits. Glycobiology 2004 Nov; 14 (11): 979-86
18. Koles K, van Berkel PH, Pieper FR, et al. N- and O-glycans of recombinant human C1 inhibitor expressed in the milk of transgenic rabbits. Glycobiology 2004 Jan; 14 (1): 51-64
19. Hack CE, Relan A, van Amersfoort ES, et al. Target levels of functional C1-inhibitor in hereditary angioedema. Allergy 2012 Jan; 67 (1): 123-30
20. Relan A, Haase G, Hack E, et al. Dose justification for recombinant human C1INH for the treatment of acute angioedema attacks in patients with hereditary angioedema [abstract no. 1186]. Allergy 2010 Jun; 65 Suppl. 92: 445-6
21. Zuraw B, Cicardi M, Levy RJ, et al. Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. J Allergy Clin Immunol 2010 Oct; 126 (4): 821-7 (plus tables e.1-14
22. Moldovan D, Reshef A, Fabiani J, et al. Efficacy and safety of recombinant human C1-inhibitor for the treatment of attacks of hereditary angioedema: European open-label extension study. Clin Exp Allergy 2012; 42: 929-35
23. McMillan CV, Speight J, Relan A, et al. Content validity of visual analogue scales to assess symptom severity of acute angioedema attacks in adults with hereditary angioedema: An interview study. Patient 2012; 5 (2): 113-26
24. 31st Annual Meeting Of The European Academy Of Allergy And Clinical Immunology; 2012 June 16-20; Geneva
25. Toubi E, Baker JW, Moldovan D, et al. Safety and efficacy evaluation of rhC1INH for the treatment of HAE attacks in adolescent patients [abstract plus poster]. 31st Annual Meeting of the European Academy of Allergy and Clinical Immunology; 2012 June 16-20; Geneva 25. Levy R, Riedl M, Lockey R, et al. Clinical efficacy of recombinant human C1 inhibitor (rhC1NH) in North-American patients with acute hereditary angioedema attacks [abstract no. P276]. Ann Allergy Asthma Immunology 2011; 107 Suppl. 5: A97
26. Reshef A, Riedl M, Moldovan D, et al. Clinical efficacy of recombinant human C1 inhibitor in patients with acute hereditary angioedema attacks [abstract]. XXII World Allergy Congress; 2011 Dec 4-8; Cancun 27
27. Zuraw B.L., Levy R.J., Suez D., et al. Clinical outcomes with recombinant human C1 inhibitor in the repeat treatment of acute attacks of hereditary angioedema in North-American patients [abstract plus poster]. American Academy of Allergy, Asthma and Immunology Annual Meeting 2011 March 18-22; San Francisc
28. Levy R, Moldovan D, Hack E, et al. Efficacy of recombinant human C1 inhibitor treatment for acute upper airway attacks in hereditary angioedema patients [abstract no. 41]. J Angioedema 2011; (Special Preview Edition printed for the 7th C1 Inhibitor Deficiency Workshop): 30.
29. Kasuma A, Relan A, Knulst AC, et al. Clinical impact of peripheral attacks in hereditary angioedema patients. Am J Med. Epub 2012 Jun 28
30. Reshef A, Moldovan D, Obtulowicz K, et al. Safety and efficacy of a weekly infusion of recombinant human C1 inhibitor (rhC1INH) for prophylaxis of hereditary angioedema (HAE) attacks [abstract plus poster]. 31st Annual Meeting of the European Academy of Allergy and Clinical Immunology; 2012 June 16-20; Geneva
31. June 16-20; Geneva 31. Hack CE, Baboeram A, Oortwijn B, et al. Immunogenicity assessment of recombinant human C1-inhibitor: An integrated analysis of clinical studies. BioDrugs 2012; 26 (5): 303-13
32. Relan A, Bakhtiari K, van Amersfoort ES, et al. Recombinant C1-inhibitor: Effects on coagulation and fibrinolysis in patients with hereditary angioedema. Biodrugs 2012 Feb; 26 (1): 43-52
33. Hack C, Relan A, Haase G, et al. IgE against rabbit allergens and the therapeutic use of recombinant human C1 inhibitor (rhC1INJ) in hereditary angioedema (HAE) [poster no. 1185-P]. 29th Annual Meeting of the European Academy of Allergy and Clinical Immunology; 2010 June 5-9; London 34. Pharming Group NV. Pharming's Ruconest for HAE granted European marketing authorization (media release 2010 Oct 28) [online]. Available from URL: Http://www.pharming. com [Accessed 2010 Nov 26]
34. Pharming completes recruitment of Ruconest US pivotal phase III study (media release 2012 July 5) [online]. Available from URL: Www.pharming. com [Accessed 2012 July 20]
35. Santarus and Pharming announce Special Protocol Assessment (SPA) agreement with FDAfor Rhucin phase III clinical study (media release 2011 Aug 4
36. [online]. Available from URL: Http://ir.santarus.com/releasedetail.cfm?re leaseid=596614 [Accessed 2012 July 20]